BRPI0513267A - variantes melhoradas de aprotinina - Google Patents

variantes melhoradas de aprotinina

Info

Publication number
BRPI0513267A
BRPI0513267A BRPI0513267-3A BRPI0513267A BRPI0513267A BR PI0513267 A BRPI0513267 A BR PI0513267A BR PI0513267 A BRPI0513267 A BR PI0513267A BR PI0513267 A BRPI0513267 A BR PI0513267A
Authority
BR
Brazil
Prior art keywords
improved
proteins
field
relates
serine protease
Prior art date
Application number
BRPI0513267-3A
Other languages
English (en)
Inventor
Kevin Lumb
Stanley Horton
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BRPI0513267A publication Critical patent/BRPI0513267A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

VARIANTES MELHORADAS DE APROTININA. A presente invenção refere-se ao campo de proteínas que inibem a atividade de serina protease. A invenção também refere-se ao campo de construtos de ácido nucléico, vetores e células hospedeiras para produzir proteínas inibidoras de serina proteases, composições farmacêuticas contendo tais proteínas e métodos para seu uso.
BRPI0513267-3A 2004-07-13 2005-07-13 variantes melhoradas de aprotinina BRPI0513267A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58765504P 2004-07-13 2004-07-13
PCT/US2005/024951 WO2006017355A2 (en) 2004-07-13 2005-07-13 Improved aprotinin variants

Publications (1)

Publication Number Publication Date
BRPI0513267A true BRPI0513267A (pt) 2008-05-06

Family

ID=35839810

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513267-3A BRPI0513267A (pt) 2004-07-13 2005-07-13 variantes melhoradas de aprotinina

Country Status (15)

Country Link
US (1) US20090005297A1 (pt)
EP (1) EP1771464A4 (pt)
JP (1) JP2008506391A (pt)
KR (1) KR20070041749A (pt)
CN (1) CN101014611A (pt)
AU (1) AU2005271708A1 (pt)
BR (1) BRPI0513267A (pt)
CA (1) CA2573368A1 (pt)
EC (1) ECSP077240A (pt)
IL (1) IL180370A0 (pt)
MA (1) MA28779B1 (pt)
MX (1) MX2007000473A (pt)
NO (1) NO20070640L (pt)
RU (1) RU2007105137A (pt)
WO (1) WO2006017355A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110301A1 (de) * 2007-03-13 2008-09-18 Bayer Schering Pharma Aktiengesellschaft Aprotinin-varianten mit verbesserten eigenschaften
WO2009030464A2 (de) * 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
CN101412995B (zh) * 2007-10-17 2011-04-06 江苏正大天晴药业股份有限公司 聚乙二醇修饰的抑肽酶及其制备方法
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
WO2010088547A1 (en) * 2009-01-29 2010-08-05 Bayer Healthcare Llc Assays for detecting pegylated blood coagulation factors
DE102011013326A1 (de) 2011-03-08 2012-09-13 Solution Shop Ag Neue Fibrinolyse-Inhibitoren und deren mdizinische Verwendung
PT2822575T (pt) * 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
US9605057B1 (en) * 2013-06-17 2017-03-28 Board Of Regents Of The University Of Texas System Endotrophin neutralization and use thereof
US20180362616A1 (en) * 2015-12-10 2018-12-20 The National Institute for Biotechnology in the Negev Ltd. VARIANTS OF AMYLOID beta-PROTEIN PRECURSOR INHIBITOR DOMAIN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233108T2 (de) * 1991-03-01 2004-04-29 Dyax Corp., Cambridge Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
US20090005297A1 (en) 2009-01-01
CN101014611A (zh) 2007-08-08
ECSP077240A (es) 2007-03-29
KR20070041749A (ko) 2007-04-19
RU2007105137A (ru) 2008-08-20
EP1771464A2 (en) 2007-04-11
EP1771464A4 (en) 2008-09-03
MX2007000473A (es) 2007-03-29
WO2006017355A2 (en) 2006-02-16
IL180370A0 (en) 2007-06-03
AU2005271708A1 (en) 2006-02-16
CA2573368A1 (en) 2006-02-16
JP2008506391A (ja) 2008-03-06
WO2006017355A3 (en) 2006-12-14
MA28779B1 (fr) 2007-08-01
NO20070640L (no) 2007-04-11

Similar Documents

Publication Publication Date Title
BRPI0513267A (pt) variantes melhoradas de aprotinina
MX2009008925A (es) Compuestos de la formula (i) como inhibidores de proteasa de serina.
Pan et al. Development of activity-based probes for trypsin-family serine proteases
BR0309671A (pt) ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
SE0201980D0 (sv) Novel compounds
ATE530643T1 (de) Säureaktive fungale protease
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
TW200637843A (en) Phenylglycinamide derivatives useful as anticoagulants
EA200800670A1 (ru) Ингибиторы сериновых протеаз
MX2009013085A (es) Metodos para mejorar el desempeño de la proteina.
MX2010004371A (es) Proteasa de streptomyces.
SE0201976D0 (sv) Novel compounds
WO2003066824A3 (en) Albumin-fused kunitz domain peptides
BRPI0517035A (pt) novos compostos
NO20081013L (no) 7-substituerte aza-indazoler, sammensetninger inneholdende disse, produksjonsmetode og anvendelse derav
BRPI0517033A (pt) novos derivados de hidantoìna como inibidores de metaloproteinase
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
EA200800357A1 (ru) Новые фармацевтические соединения
TR199902751T2 (xx) Proteaz inhibit�rleri.
BRPI0507613A (pt) expressão de plasminogênio e microplasminogênio em lentilha d'água
SE0201977D0 (sv) Novel compounds
WO2003095475A8 (en) Peptide compounds and their use as protease substrates
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav
MX9702776A (es) Proteinas de proteasa de pulgas, moleculas de acido nucleico, y usos de las mismas.
Filippova et al. New glutamine-containing substrates for the assay of cysteine peptidases from the C1 papain family

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.